epiCaPture - A new urine test to detect high-risk prostate cancer- Licensing Opportunity from Trinity College Dublin - July 2015 front page preview

epiCaPture - A new urine test to detect high-risk prostate cancer- Licensing Opportunity from Trinity College Dublin - July 2015

A urine test that detects the presence of prostate cancer cells and measures biochemical changes at 6 genes. 
It Identifies which men need a biopsy to diagnose prostate cancer and also uses an algorithm to assess prostat...

pdf 1.2MB

Biomarker for Colorectal Cancer - Licensing Opportunity from Trinity College Dublin - July 2015 front page preview

Biomarker for Colorectal Cancer - Licensing Opportunity from Trinity College Dublin - July 2015

The pathogenesis of 15% of human cancers has been linked to inflammation. One of the most prevalent inflammation driven cancers is colitis-associated colorectal cancer (CRC). Annually Ireland - CRC is responsible for 15%...

pdf 1MB

Dissolution Simulation - Licensing Opportunity from Trinity College Dublin - July 2015 front page preview

Dissolution Simulation - Licensing Opportunity from Trinity College Dublin - July 2015

This software code allows generation of a simulated profile of particles dissolving over time. It includes simulation of dissolution under a range of pharmaceutical industry-standard test conditions.

pdf 1.1MB

Cartilage Repair Therapy - Licensing Opportunity from Trinity College Dublin - July 2015 front page preview

Cartilage Repair Therapy - Licensing Opportunity from Trinity College Dublin - July 2015

Articular cartilage injury or degeneration is a common disorder of joints, affecting people of all ages. More than 500,000 cartilage repair procedures are performed annually in the United States alone. The intrinsic rang...

pdf 1.1MB

Novel Biomarker for Multiple Myeloma Diagnosis and Prognosis - Licensing Opportunity from National University of Ireland Galway - March 2015 front page preview

Novel Biomarker for Multiple Myeloma Diagnosis and Prognosis - Licensing Opportunity from National University of Ireland Galway - March 2015

Multiple Myeloma is a highly prevalent disease accounting for 1-2% of all cancers, with a market size for treatments estimated to grow to $7 billion by 2020. This technology will prove to be extremely valuable in fightin...

pdf 1.2MB